MedLabs InnoTalk Series
Patent Strategies for Biotechnology Startups
Tuesday , March 8th , Online Zoom Webinar
We are delighted to have Dr. Xiaoban Xin with us in this InnoTalk Event. Dr. Xin is an experienced patent attorney with a solid scientific background in life sciences at Rothwell Figg IP Professionals. Joining as moderator, Dr. Ella Li is the CEO of ZGC Capital and the partner of ZGC U.S. Fund, leading ZGC’s team in investment and healthcare accelerator operation.
The one-hour-long webinar consists of a welcome intro by Dr. Ella Li, a 40-minute informative speech, and a Q&A session.
ATTENDEES WILL LEARN
Basic requirements for patentability of bio/pharma technologies.
How to build a valuable patent portfolio to protect your technology in 2022?
Strategies to evaluate and manage the risks of infringing others’ patents.
Step-to-step tips for preparing for patent due diligence.
Live Q&A Session for all attendees joining the webinar.
Xiaoban Xin, Ph.D.
Patent Attorney, Rothwell Figg IP Professionals
Dr. Xiaoban Xin assists companies and research institutes with preparing and prosecuting patent applications, patent portfolio management, strategic patent counseling, and due diligence.
Xiaoban has specific experience working with clients in the fields of biotechnology, including gene editing (e.g., CRISPR technology), next generation sequencing, immunotherapy, cell therapy, biologics, small molecules, stem cells, genetically modified animals, and pharmaceutical formulations. Xiaoban also has extensive experience in the fields of medical device, chemical engineering and materials, energy and cleantech, mechanical engineering, and health IT.
Prior to practicing law, Xiaoban was a Technology Transfer Fellow at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institute of Health (NIH), where he managed IP portfolios and drafted technology transfer agreements.
Xiaoban received his Ph.D. from The University of Texas Health Science Center and post-doc training at the Johns Hopkins University School of Medicine, where he studied molecular mechanisms underlying diabetes and retinopathy. His research has been published in a number of professional journals.
Dr. Ella Li（moderator）
Partner of ZGC US Fund, CEO of ZGC Capital
Dr. Ella Li the CEO of ZGC Capital and also the partner of ZGC U.S. Fund, leading ZGC’s team in investment and incubator operation. She’ established and managed several VC and fund of funds, including one with portfolio funds including KPCB, Menlo, Andreessen Horowitz, Accel and Foundation Capital. She is also the founder of Medlabs healthcare accelerator, providing companies with funding, mentorship and key resources to transform healthcare.
Dr. Li has 15+ years of experience in pharmaceutical and biotechnology sectors and has rich experiences in therapeutic investment opportunities from discovery and clinical proof-of-concept to commercialization. She also serves as board advisor, consultant and mentor in several major VC, accelerators, and startups. Dr. Ella Li earned her B.S. and M.S. degrees from Peking University School of Pharmacy, Ph.D. from the University of Texas Health Science Centers, and completed her postdoctoral fellowship from Harvard Medical School. Ella has extensive publications in prestigious journals with IMF over 10 including Nature Communication, Cell Metabolism, Journal of Clinical Investigation, PNAS, Molecular Cell, Diabetes etc.